Zevra Therapeutics Files Proxy Materials
Ticker: ZVRA · Form: DEFA14A · Filed: Apr 21, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | DEFA14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, regulatory
Related Tickers: ZEVRA
TL;DR
ZEVRA filed proxy docs, no fee. Formerly KMPH.
AI Summary
Zevra Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on April 21, 2025. This filing relates to the company's proxy statement and indicates no fee was required for this filing. The company was formerly known as KemPharm, Inc. and is incorporated in Delaware.
Why It Matters
This filing is a routine regulatory document that provides shareholders with information related to upcoming corporate decisions or meetings, impacting their voting rights and understanding of company governance.
Risk Assessment
Risk Level: low — This filing is a standard DEFA14A, indicating routine proxy statement information rather than a significant event like an acquisition or major financial distress.
Key Players & Entities
- ZEVRA THERAPEUTICS, INC. (company) — Registrant
- KEMPHARM, INC (company) — Former company name
- 0001193125-25-086311 (filing_id) — Accession Number
- 20250421 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A, specifically 'Definitive Additional Materials' related to a proxy statement.
What is the filing date?
The filing date is April 21, 2025.
What is the company's current name?
The company's current name is Zevra Therapeutics, Inc.
What was the company's former name?
The company was formerly known as KemPharm, Inc.
Was there a fee required for this filing?
No fee was required for this filing.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 21, 2025 regarding ZEVRA THERAPEUTICS, INC. (ZVRA).